COST-EFFECTIVENESS CONSEQUENCES OF OBESITY IN T2DM BY INSULIN ANALOGUE THERAPY

被引：0

作者：

Jozsa, Z. ^{[1
]}

Toth, E. ^{[2
]}

Nagy, B. ^{[2
]}

机构：

[1] Novo Nordisk Hungary Ltd, Budapest, Hungary

[2] Healthware Ltd, Budapest, Hungary

来源：

VALUE IN HEALTH | 2010年 / 13卷 / 07期

关键词：

D O I：

10.1016/S1098-3015(11)72090-3

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A289 / A289

页数：1

共 50 条

[21] Clinical inertia in insulin therapy in T2DM in primary care
Harris, Stewart B.
Kapor, Jovana
DIABETES, 2008, 57 : A136 - A136
[22] In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y
Sarma, Shohinee
Lipscombe, Lorraine L.
ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : JC70 - JC70
[23] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
Willis, M.
He, J.
Neslusan, C.
Johansen, P.
Worbes-cerezo, M.
VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
[24] ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL
McEwan, P.
Evans, L. M.
Bergenheim, K.
VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
[25] COST-EFFECTIVENESS OF INSULIN GLARGINE PLUS ORAL ANTIDIABETIC DRUGS (OADS) COMPARED TO PREMIXED INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING
Minshall, M. E.
Sauriol, L.
VALUE IN HEALTH, 2008, 11 (06) : A502 - A502
[26] Biliopancreatic diversion restores acute insulin response in T2DM with morbid obesity
Briatore, Lucia
Salani, Barbara
Maggi, Davide
Andraghetti, Gabriella
Adami, Gianfranco
Cordera, Renzo
DIABETES, 2007, 56 : A381 - A381
[27] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
Thompson, G.
Schroeder, M.
Neslusan, C.
Willis, M.
Johansen, P.
Teschemaker, A.
DIABETOLOGIA, 2014, 57 : S330 - S330
[28] COST EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH T2DM AND HIGH CV RISK IN CANADA
Mettam, S. R.
Bajaj, H.
Kansal, A. R.
Kandaswamy, P.
VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
[29] Designing a new therapy for T2DM
Greenhill, Claire
NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (12) : 684 - 684
[30] Antihelminthic drug for T2DM therapy?
Joana Osório
Nature Reviews Endocrinology, 2014, 10 (12) : 702 - 702

← 1 2 3 4 5 →